References
- Kumar SK. Bortezomib for myeloma: optimizing treatment strategies. Commun Oncol. 2012;9:272–273.
- Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252–264.
- Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice pattern across Europe. Br J Haematol. 2016;175:66–76.
- Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
- Lassalle A, Thomaré P, Fronteau C, et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol. 2016;27:314–318.
- Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100:964–969.
- Larocca A, Bringhen S, Petrucci MT, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia. 2016; 30:1320–1326.
- Minarik J, Pavlicek P, Pour L, et al. Subcutaneos Bortezomib in multiple myeloma patients induces similar therapeutic responce rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLos One. 2015;10:e0123866.
- Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol. 2012;3:117–124.
- Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide versus bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomised controlled trial. JCO. 2010;28:5101–5109.
- Durie BGM, Harousseau JL, San Miguel J, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
- National Cancer Institute [Internet]. National Cancer Institute Cancer therapy evaluation Program common terminology criteria for adverse events. v4.03. [cited 2010 Jun 14]. Available from: https://ctep.cancer.gov/…/electronic_applications/…/ctcaev3.pdf
- Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–4753.
- Kurtin S, Knop CS, Milliron T. Subcutaneous administration of bortezomib: strategies to reduce injection site reactions. J Adv Pract Oncol. 2012;3:406–410.